Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

Cited In for PubMed (Select 21693741)

1.

Effect of Omega-3 Fatty Acid on the Fatty Acid Content of the Erythrocyte Membrane and Proteinuria in Patients with Diabetic Nephropathy.

Lee SM, Chung SH, Park Y, Park MK, Son YK, Kim SE, An WS.

Int J Endocrinol. 2015;2015:208121. doi: 10.1155/2015/208121. Epub 2015 May 18.

2.

Acute Kidney Injury in Severe Sepsis and Septic Shock in Patients with and without Diabetes Mellitus: A Multicenter Study.

Venot M, Weis L, Clec'h C, Darmon M, Allaouchiche B, Goldgran-Tolédano D, Garrouste-Orgeas M, Adrie C, Timsit JF, Azoulay E.

PLoS One. 2015 May 28;10(5):e0127411. doi: 10.1371/journal.pone.0127411. eCollection 2015.

3.

Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial.

Li P, Chen Y, Liu J, Hong J, Deng Y, Yang F, Jin X, Gao J, Li J, Fang H, Liu G, Shi L, Du J, Li Y, Yan M, Wen Y, Yang W.

PLoS One. 2015 May 4;10(5):e0126027. doi: 10.1371/journal.pone.0126027. eCollection 2015.

4.

Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.

Wang ZS, Xiong F, Xie XH, Chen D, Pan JH, Cheng L.

BMC Nephrol. 2015 Mar 31;16:44. doi: 10.1186/s12882-015-0031-7.

5.

Five-year incidence of chronic kidney disease (stage 3-5) and associated risk factors in a Spanish cohort: the MADIABETES Study.

Salinero-Fort MA, San Andrés-Rebollo FJ, de Burgos-Lunar C, Gómez-Campelo P, Chico-Moraleja RM, López de Andrés A, Jiménez-García R; MADIABETES Group.

PLoS One. 2015 Apr 9;10(4):e0122030. doi: 10.1371/journal.pone.0122030. eCollection 2015.

6.

Causes of the change in the rates of mortality and severe complications of diabetes mellitus: 1992-2012.

Yashkin AP, Picone G, Sloan F.

Med Care. 2015 Mar;53(3):268-75. doi: 10.1097/MLR.0000000000000309.

PMID:
25675404
7.

Incidence of renal replacement therapy for diabetic nephropathy in the Netherlands: Dutch diabetes estimates (DUDE)-3.

van Dijk PR, Kramer A, Logtenberg SJ, Hoitsma AJ, Kleefstra N, Jager KJ, Bilo HJ.

BMJ Open. 2015 Jan 30;5(1):e005624. doi: 10.1136/bmjopen-2014-005624.

8.

Risks of rapid decline renal function in patients with type 2 diabetes.

Sheen YJ, Sheu WH.

World J Diabetes. 2014 Dec 15;5(6):835-46. doi: 10.4239/wjd.v5.i6.835. Review.

9.

Complications and comorbidities of T2DM in adolescents: findings from the TODAY clinical trial.

Tryggestad JB, Willi SM.

J Diabetes Complications. 2015 Mar;29(2):307-12. doi: 10.1016/j.jdiacomp.2014.10.009. Epub 2014 Oct 29. Review.

PMID:
25468310
10.

Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease).

Szczech LA, Stewart RC, Su HL, DeLoskey RJ, Astor BC, Fox CH, McCullough PA, Vassalotti JA.

PLoS One. 2014 Nov 26;9(11):e110535. doi: 10.1371/journal.pone.0110535. eCollection 2014.

11.

Insulin signaling: implications for podocyte biology in diabetic kidney disease.

Coward R, Fornoni A.

Curr Opin Nephrol Hypertens. 2015 Jan;24(1):104-10. doi: 10.1097/MNH.0000000000000078.

12.

Inhibition of kidney proximal tubular glucose reabsorption does not prevent against diabetic nephropathy in type 1 diabetic eNOS knockout mice.

Gangadharan Komala M, Gross S, Mudaliar H, Huang C, Pegg K, Mather A, Shen S, Pollock CA, Panchapakesan U.

PLoS One. 2014 Nov 4;9(11):e108994. doi: 10.1371/journal.pone.0108994. eCollection 2014.

13.

Fibroblast growth factor 23 and incident CKD in type 2 diabetes.

Isakova T, Craven TE, Lee J, Scialla JJ, Xie H, Wahl P, Marcovina SM, Byington RP, Wolf M.

Clin J Am Soc Nephrol. 2015 Jan 7;10(1):29-38. doi: 10.2215/CJN.06190614. Epub 2014 Oct 24.

PMID:
25343949
14.

Diabetes treatment in patients with renal disease: Is the landscape clear enough?

Ioannidis I.

World J Diabetes. 2014 Oct 15;5(5):651-8. doi: 10.4239/wjd.v5.i5.651. Review.

15.

Self-rated health and adverse events in CKD.

Robinson-Cohen C, Hall YN, Katz R, Rivara MB, de Boer IH, Kestenbaum BR, Himmelfarb J.

Clin J Am Soc Nephrol. 2014 Dec 5;9(12):2044-51. doi: 10.2215/CJN.03140314. Epub 2014 Oct 9.

PMID:
25301857
16.

Diabetic nephropathy for the primary care provider: new understandings on early detection and treatment.

Kowalski A, Krikorian A, Lerma EV.

Ochsner J. 2014 Fall;14(3):369-79. Review.

17.

Diabetic kidney disease: a report from an ADA Consensus Conference.

Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME.

Diabetes Care. 2014 Oct;37(10):2864-83. doi: 10.2337/dc14-1296.

PMID:
25249672
18.

Diabetic kidney disease: from epidemiology to clinical perspectives.

Park CW.

Diabetes Metab J. 2014 Aug;38(4):252-60. doi: 10.4093/dmj.2014.38.4.252. Review.

19.

Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate renal impairment.

Inagaki N, Kondo K, Yoshinari T, Ishii M, Sakai M, Kuki H, Furihata K.

Clin Drug Investig. 2014 Oct;34(10):731-42. doi: 10.1007/s40261-014-0226-x.

20.

Is there a sweet spot for Nrf2 activation in the treatment of diabetic kidney disease?

Hall ET, Bhalla V.

Diabetes. 2014 Sep;63(9):2904-5. doi: 10.2337/db14-0829. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk